RPRX

Royalty Pharma plc

NasdaqGSUSDEQUITY DELAYED

61.31

▲ 0.73 (1.21%)

MARKET · —

Price

Open

60.58

Prev close

60.58

Day high

61.55

Day low

60.37

Volume

1.94M

Market cap

—

P/E (TTM)

—

52W range

34.08 – 62.13

Trailing performance

Price return · vs SPY

Returnvs SPY

+4.62% +6.0%

+3.88% +0.1%

+14.49% +11.4%

+35.88% +24.8%

YTD

+58.67% +46.4%

+66.24% +46.2%

+106.50% +32.3%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

59.49

+3.06% from price

SMA 20

58.83

+4.21% from price

SMA 50

57.35

+6.90% from price

SMA 100

54.30

+12.91% from price

SMA 200

48.08

+27.50% from price

EMA 12

59.61

+2.85% from price

EMA 26

58.69

+4.46% from price

EMA 50

57.32

+6.96% from price

RSI (14)

63.4

Neutral

MACD (12,26,9)

0.92

Hist 0.26

ATR (14)

1.53

2.50% of price

Realised vol 30D

23.8%

Annualised

Bollinger upper

61.48

20, 2σ

Bollinger lower

56.19

20, 2σ

50 / 200 cross

Golden

57.35 vs 48.08

Trend bias

Above 200

+27.50%

Risk profile

Daily returns · 1Y window

Beta vs SPY

0.23

Less volatile than market

Correlation to SPY

0.13

Largely independent

Realised vol 30D

23.8%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-6.6%

Peak to trough

Max drawdown 5Y

-45.6%

Peak to trough

ATR 14

1.53

2.50% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 61.31

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

RPRX · links out to the publisher

Royalty Pharma plc (RPRX) vs. AstraZeneca PLC (AZN): Which Biopharma Model Offers the Better Growth Story? Insider Monkey · 9d ago Royalty Pharma (RPRX) Crossed Above the 20-Day Moving Average: What That Means for Investors Zacks · 9d ago Zealand Pharma (CPSE:ZEAL) Stock Looks Fairly Valued After Its 90% Five Year Run Simply Wall St. · 9d ago Zealand Pharma (CPSE:ZEAL) On Its Royalty Pharma Deal And The Fair Value Debate Simply Wall St. · 10d ago Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million GlobeNewswire · 10d ago Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide GlobeNewswire · 10d ago Royalty Pharma (RPRX) Q2 2026 Earnings Call Transcript Motley Fool · 10d ago Revolution Medicines Inc (RVMD) (Q2 2026) Earnings Call Highlights: Daraxonrasib Poised to ... GuruFocus.com · 17d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.